Credibility Crisis: Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA

Credibility Crisis:Survey FDA Scientists – Death in NIH-AIDS Trial – Tauzin Moves to PhRMA Thu, 16 Dec 2004 A credibility crisis in medical research is smoldering: like the Enron accounting scandal, the prescription-drug debacle is a matter of systemic corruption, including gross and widespread failure by the regulatory process. Unlike…

Featured News

AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…

Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D

Psychopharmacology in Turmoil: David Healy, MD Presentation Columbia + Debate Dr. Joseph Coyne, Ph.D Fri, 9 Dec 2005 Recent reports describing a determined effort to pathologize US infants and toddlers who are being declared to suffer from “severe mental disorders”–the latest, most aggressively marketed diagnosis for children is Bipolar disorder,…

AHRP Opposes Drug Implants for Psychiatric Patients

AHRP Opposes Drug Implants for Psychiatric Patients Those promoting the implants focus on its delivery of continuous sustained drug action to ensure that patients take the drugs they’re prescribed, presumably to prevent relapse. But critics who are familiar with widespread psychotropic drug prescribing abuses recognize the serious potential for harm…

Dr. David Healy Addresses Credibility Crisis-at Columbia University Oct. 20

Additional information as of late Wed Oct 19: Although I was assured that attendance for a presentation by Dr. David Healy (at Columbia University School of Public Health on Oct. 20 at 12:30) would be open to the public, a problem seems to have emerged after an AHRP Infomail about…

FDA Asks Antidepressant drug companies to add Cautions on labels

FDA Asks Antidepressant drug companies to add Cautions on labels Mon, 22 Mar 2004 The FDA has “requested” drug companies to put prominent warnings on the labels of 10 antidepressant drugs, “to include stronger cautions and warnings about the need to monitor patients for the worsening of depression and the…